New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics

Journal of Proteome Research

Volumn 13, Issue 5, 2014, Pages 2445-2452

  Ku, Xin ^a   Heinzlmeir, Stephanie ^a,b   Helm, Dominic ^a   Médard, Guillaume ^a   Kuster, Bernhard ^a,b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Munich Center for Integrated Protein Science   (Germany)

Author keywords

axitinib; chemical proteomics; kinobeads; pazopanib

Indexed keywords

AXITINIB; PAZOPANIB; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; STEM CELL FACTOR; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ARTICLE; CANCER CELL LINE; CELL LYSATE; CONTROLLED STUDY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PLACENTA; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; K562 CELL LINE; LIQUID CHROMATOGRAPHY; METABOLISM; MOLECULAR DOCKING; MOLECULAR GENETICS; MOLECULAR LIBRARY; PHARMACOLOGY; PREGNANCY; PROCEDURES; PROTEOMICS; SEQUENCE HOMOLOGY; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; BINDING, COMPETITIVE; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; K562 CELLS; MODELS, CHEMICAL; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PLACENTA; PREGNANCY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTEOMICS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID; SMALL MOLECULE LIBRARIES; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84899863913     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr401247t     Document Type: Article

References (42)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298 (5600) 1912-1934
2. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002, 1 (4) 309-315
3. Drews, J. Case histories, magic bullets and the state of drug discovery Nat. Rev. Drug Discovery 2006, 5 (8) 635-640
4. Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D. H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N. S.; Kuster, B.; Lackey, K. E.; Mazzafera, P.; Tomkinson, N. C.; Willson, T. M.; Workman, P.; Zuercher, W. J. A public-private partnership to unlock the untargeted kinome Nat. Chem. Biol. 2012, 9 (1) 3-6
5. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26 (1) 127-132
6. Anastassiadis, T.; Deacon, S. W.; Devarajan, K.; Ma, H.; Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1039-1045
7. Zinn, N.; Hopf, C.; Drewes, G.; Bantscheff, M. Mass spectrometry approaches to monitor protein-drug interactions Methods 2012, 57 (4) 430-440
8. Schirle, M.; Bantscheff, M.; Kuster, B. Mass spectrometry-based proteomics in preclinical drug discovery Chem. Biol. 2012, 19 (1) 72-84
9. Bantscheff, M.; Drewes, G. Chemoproteomic approaches to drug target identification and drug profiling Bioorg. Med. Chem. 2012, 20 (6) 1973-1978
10. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 2007, 25 (9) 1035-1044
11. Bantscheff, M.; Kuster, B. Quantitative mass spectrometry in proteomics Anal Bioanal Chem. 2012, 404 (4) 937-938
12. Godl, K.; Wissing, J.; Kurtenbach, A.; Habenberger, P.; Blencke, S.; Gutbrod, H.; Salassidis, K.; Stein-Gerlach, M.; Missio, A.; Cotten, M.; Daub, H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (26) 15434-15439
13. Graves, P. R.; Kwiek, J. J.; Fadden, P.; Ray, R.; Hardeman, K.; Coley, A. M.; Foley, M.; Haystead, T. A. Discovery of novel targets of quinoline drugs in the human purine binding proteome Mol. Pharmacol. 2002, 62 (6) 1364-1372
14. Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; Nomanbhoy, T. K.; Wu, M.; Weissig, H.; Aban, A.; Chun, D.; Tanner, S.; Kozarich, J. W. Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 2007, 46 (2) 350-358
15. Liu, Y.; Patricelli, M. P.; Cravatt, B. F. Activity-based protein profiling: the serine hydrolases Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (26) 14694-14699
16. Lemeer, S.; Zorgiebel, C.; Ruprecht, B.; Kohl, K.; Kuster, B. Comparing Immobilized Kinase Inhibitors and Covalent ATP Probes for Proteomic Profiling of Kinase Expression and Drug Selectivity J. Proteome Res. 2013, 12 (4) 1723-1731
17. Bantscheff, M.; Hopf, C.; Savitski, M. M.; Dittmann, A.; Grandi, P.; Michon, A. M.; Schlegl, J.; Abraham, Y.; Becher, I.; Bergamini, G.; Boesche, M.; Delling, M.; Dumpelfeld, B.; Eberhard, D.; Huthmacher, C.; Mathieson, T.; Poeckel, D.; Reader, V.; Strunk, K.; Sweetman, G.; Kruse, U.; Neubauer, G.; Ramsden, N. G.; Drewes, G. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nat. Biotechnol. 2011, 29 (3) 255-265
18. Dadvar, P.; O'Flaherty, M.; Scholten, A.; Rumpel, K.; Heck, A. J. A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124 Mol. Biosyst. 2009, 5 (5) 472-482
19. Godl, K.; Gruss, O. J.; Eickhoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z.; Keri, G.; Muller, S.; Cotten, M.; Ullrich, A.; Daub, H. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling Cancer Res. 2005, 65 (15) 6919-6926
20. Ku, X.; Heinzlmeir, S.; Liu, X.; Medard, G.; Kuster, B. A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors J. Proteomics 2014, 96 (16) 44-55
21. Oppermann, F. S.; Gnad, F.; Olsen, J. V.; Hornberger, R.; Greff, Z.; Keri, G.; Mann, M.; Daub, H. Large-scale proteomics analysis of the human kinome Mol. Cell. Proteomics 2009, 8 (7) 1751-1764
22. Pachl, F.; Plattner, P.; Ruprecht, B.; Medard, G.; Sewald, N.; Kuster, B. Characterization of a chemical affinity probe targeting Akt kinases J. Proteome Res. 2013, 12 (8) 3792-3800
23. Schirle, M.; Petrella, E. C.; Brittain, S. M.; Schwalb, D.; Harrington, E.; Cornella-Taracido, I.; Tallarico, J. A. Kinase inhibitor profiling using chemoproteomics Methods Mol. Biol. 2012, 795, 161-177
24. Wu, Z.; Doondeea, J. B.; Gholami, A. M.; Janning, M. C.; Lemeer, S.; Kramer, K.; Eccles, S. A.; Gollin, S. M.; Grenman, R.; Walch, A.; Feller, S. M.; Kuster, B. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer Mol. Cell. Proteomics 2011, 10 (12) M111 011635
25. Wu, Z.; Moghaddas Gholami, A.; Kuster, B. Systematic identification of the HSP90 candidate regulated proteome Mol. Cell. Proteomics 2012, 11 (6) M111 016675
26. Zhang, L.; Holmes, I. P.; Hochgrafe, F.; Walker, S. R.; Ali, N. A.; Humphrey, E. S.; Wu, J.; de Silva, M.; Kersten, W. J.; Connor, T.; Falk, H.; Allan, L.; Street, I. P.; Bentley, J. D.; Pilling, P. A.; Monahan, B. J.; Peat, T. S.; Daly, R. J. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling J. Proteome Res. 2013, 12 (7) 3104-3116
27. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120) J. Med. Chem. 2009, 52 (14) 4466-4480
28. Hilberg, F.; Roth, G. J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W. J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 2008, 68 (12) 4774-4782
29. Deeks, E. D. Pazopanib: in advanced soft tissue sarcoma Drugs 2012, 72 (16) 2129-2140
30. Hu-Lowe, D. D.; Zou, H. Y.; Grazzini, M. L.; Hallin, M. E.; Wickman, G. R.; Amundson, K.; Chen, J. H.; Rewolinski, D. A.; Yamazaki, S.; Wu, E. Y.; McTigue, M. A.; Murray, B. W.; Kania, R. S.; O'Connor, P.; Shalinsky, D. R.; Bender, S. L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin. Cancer Res. 2008, 14 (22) 7272-7283
31. Sharma, K.; Weber, C.; Bairlein, M.; Greff, Z.; Keri, G.; Cox, J.; Olsen, J. V.; Daub, H. Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 2009, 6 (10) 741-744
32. Sonpavde, G.; Hutson, T. E.; Rini, B. I. Axitinib for renal cell carcinoma Expert Opin. Invest. Drugs 2008, 17 (5) 741-748
33. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1046-1051
34. Takaya, K.; Yoshimasa, T.; Arai, H.; Tamura, N.; Miyamoto, Y.; Itoh, H.; Nakao, K. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin J. Mol. Med. 1996, 74 (10) 617-621
35. Marumoto, T.; Zhang, D.; Saya, H. Aurora-A-a guardian of poles Nat. Rev. Cancer 2005, 5 (1) 42-50
36. Fu, J.; Bian, M.; Jiang, Q.; Zhang, C. Roles of Aurora kinases in mitosis and tumorigenesis Mol. Cancer Res. 2007, 5 (1) 1-10
37. Borrello, M. G.; Ardini, E.; Locati, L. D.; Greco, A.; Licitra, L.; Pierotti, M. A. RET inhibition: implications in cancer therapy Expert Opin. Ther. Targets 2013, 17 (4) 403-419
38. Mehra, R.; Serebriiskii, I. G.; Burtness, B.; Astsaturov, I.; Golemis, E. A. Aurora kinases in head and neck cancer Lancet Oncol. 2013, 14 (10) e425-e435
39. Khurana, T.; Khurana, B.; Noegel, A. A. LIM proteins: association with the actin cytoskeleton Protoplasma 2002, 219 (1-2) 1-12
40. Yoshioka, K.; Foletta, V.; Bernard, O.; Itoh, K. A role for LIM kinase in cancer invasion Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (12) 7247-7252
41. Vlecken, D. H.; Bagowski, C. P. LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells Zebrafish 2009, 6 (4) 433-439
42. Isham, C. R.; Bossou, A. R.; Negron, V.; Fisher, K. E.; Kumar, R.; Marlow, L.; Lingle, W. L.; Smallridge, R. C.; Sherman, E. J.; Suman, V. J.; Copland, J. A.; Bible, K. C. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer Sci. Transl Med. 2013, 5 (166) 166ra3